|
Up to One in three patients on antiplatelet medications such as aspirin and Plavix may not be responding adequately to their antiplatelet medications.(1) Patients who are not responding adequately to their antiplatelet medications may be at 5 to 10 times greater risk for ischemic events.(2-5)
The rapid and easy-to-use VerifyNow System provides physicians with data in minutes.
The VerifyNow System:
• 3 easy steps
• Results in minutes
• Whole-blood, closed tube samples
• No pipetting
• No sample preparation
Backed by numerous peer-reviewed studies that demonstrate the VerifyNow System’s clinical utility and analytical performance, the VerifyNow System provides information to help assess a patient’s response to all antiplatelet therapies:
VerifyNow P2Y12 Test:
- P2Y12 inhibitors (i.e., clopidogrel/Plavix, prasugrel/Efient, ticlopidine/Ticlid)
VerifyNow Aspirin Test:
- Aspirin
VerifyNow IIb/IIIa Test:
- GP IIb/IIIa inhibitors (i.e., abciximab/ReoPro, eptifibatide/Integrilin)
The VerifyNow System from Accumetrics is available worldwide through an international network of distributors. Please visit us at www.accumetrics.com/distributors/ for your local distributor or email us at support@accumetrics.com for more information.
1. Dupont, AG. et al. Thromb Res. 2009 May; 124(1):6-13.
2. Patti, G. et al. J Am Coll Cardiol. 2008; 52:1128–33.
3. Marcucci, R. et al. Cir. 2009;119(2):237-42.
4. Cuisset, T. et al. Am J Cardio. 2008 Jun 15; 101(12):1700-3.
5. Price, MJ. et al. Eur Heart J. 2008 Apr; 29(8):992-1000.
6. Wiviott, SD. et al. N Engl J Med. 2007 Nov; 357:2001-15.
Accumetrics logo and VerifyNow are registered trademarks of Accumetrics, Inc., ReoPro is a registered trademark of Centocor, Inc. Integrilin is a registered trademark of Millennium Pharmaceuticals. Plavix is a registered trademark of Sanofi-Aventis. Efient is a registered trademark of Eli Lilly and Company.
|
